Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Aarhus
With
H. Lundbeck A/S
Around 20 % of patients with schizophrenia are treatment-resistant. Clozapine is still the drug of choice for these patients but 2/3 will not respond adequately to clozapine. In the study clozapine treatment is augmented with sertindole. Patients are randomized to either clozapine or sertindole for 12 weeks and continue in a open-label study with sertindole for 12 weeks. The purpose of the open-label study is to determine whether clozapine dosage can be reduced due to the addition of sertindole.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
ICD10 diagnosis of schizophrenia (F20.0-3)
Clozapine treatment minimum 6 months
Total PANSS \>65
No antipsychotic other than clozapine drug 1 month prior inclusion
You may not be if
QTc \>500 ms
Violence to SPC of clozapine or Serdolect
Major depression
Significant substance misuse interfering with participating in the study
